Biotech stock Halozyme Therapeutics (HALO) is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised its 2025 outlook last month. Halozyme has developed a proprietary technology using an enzyme which helps deliver drugs and fluids under the skin via injection, named Enhanze. Drugmakers, including…
